Recruiting
Phase 3

Cilostazol

Sponsor:

Stanford University

Code:

NCT07174414

Conditions

Stroke Recurrence

Myocardial Infarction

Vascular Death

Ischemic Stroke

TIA (Transient Ischemic Attack)

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Cilostazol 100 mg Tablets

Placebo

Study Details

Brief summary:

The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months.

To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it.

Participants will:

  • Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine.
  • Not know which one they are taking, and neither will the study team, which keeps the results fair.
  • Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding.

See the Clarity study website for more information:

https://www.claritystrokestudy.org/

Conditions

Stroke Recurrence

Myocardial Infarction

Vascular Death

Ischemic Stroke

TIA (Transient Ischemic Attack)

Study ID

NCT07174414

Start date

Oct 15, 2026

Status verified date

Oct, 2026

Completion date

Jul, 2031

Anticipated

Primary completion date

Jul, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. ≥40 years
2. Ischemic stroke or high-risk TIA (ABCD2 score ≥6)
3. Can be randomized within 180 days after ischemic stroke or high-risk TIA
4. Treatment with single or dual antithrombotic therapy with aspirin, clopidogrel and/or ticagrelor per international and/or national guidelines
5. Two or more of the following risk factors: age 65 years or older, hypertension, diabetes mellitus, history of ischemic stroke other than the qualifying event for this trial, currently smoking, peripheral arterial disease, coronary artery disease including prior MI, aortic atherosclerotic plaque ≥4 mm, ≥50% stenosis or occlusion of a major intracranial artery (ICA, M1, M2, A1, P1, vertebral, or basilar) or extracranial artery (ICA or vertebral)
6. In the opinion of the site investigator, patient is medically stable, capable of participating in the trial, and willing and able to attend follow-up
7. Able to receive study drug by mail and able to begin taking study drug promptly after receipt
8. Provision of signed and dated informed consent form by patient or legally authorized representative

Exclusion Criteria:

1. Atrial fibrillation, mechanical heart valve, or left ventricular assist device
2. Use of prohibited medication (as specified in the MOP)
3. Modified Rankin Scale 5
4. Planned cardiac surgery, percutaneous coronary intervention, carotid endarterectomy or stenting (patients are eligible post-procedure)
5. History of symptomatic non-traumatic intracerebral hemorrhage within last 2 years
6. Known thrombocytopenia (platelet count ≤100,000 per microliter (µL))
7. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
8. Pregnant, breast-feeding, or of child-bearing potential but not on birth control
9. Confirmed diagnosis of heart failure with current or prior symptoms or signs (e.g. paroxysmal nocturnal dyspnea, reduced exercise tolerance, ankle swelling, elevated jugular venous pressure)
10. Hypersensitivity to cilostazol or any component of the formulation (e.g. anaphylaxis, angioedema)
11. Currently enrolled in an investigational intervention study
12. Life expectancy less than 6 months
13. Participant does not allow contacting of their surrogate (e.g. family member or friend) or health care practitioner to obtain health information should participant become unwilling or unable to follow the study schedule.
14. Participants who are incarcerated, including prisoners or participants compulsorily detained for treatment of psychiatric disease.

Study Design

Enrollment

2000 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Cilostazol

Participants take oral cilostazol until a study endpoint occurs, they reach maximum follow up duration (5 years), the participant withdraws, or the study ends.

placebo comparator: Placebo

Participants take oral placebo until a study endpoint occurs, they reach maximum follow up duration (5 years), the participant withdraws, or the study ends.

Interventions

Cilostazol 100 mg Tablets

The standard dosing regimen is an initial 2-week period during which participants take one tablet of cilostazol (100 mg) orally once daily followed by a maintenance phase in which they take one tablet twice daily. For participants who are on certain interacting drugs or who experience adverse reactions on the standard dosing regimen, the dose is reduced to half a tablet twice daily.

Placebo

The standard dosing regimen is an initial 2-week period during which participants take one placebo tablet, which matches cilostazol 100 mg tablets, orally once daily followed by a maintenance phase in which they take one tablet twice daily. For participants who are on certain interacting drugs or who experience adverse reactions on the standard dosing regimen, the dose is reduced to half a tablet twice daily.

Primary outcome measure

  • Time to first occurrence of any component of the composite of ischemic stroke, acute myocardial infarction, or ischemic vascular death (MACE). [ Time Frame: Up to 5 years after randomization ]

Central Contacts and Locations

Locations

University of Alabama Hospital - Birmingham

Recruiting

Birmingham, Alabama, United States, 35249

Contacts

Chandler Regional Medical Center

Recruiting

Chandler, Arizona, United States, 85224

Contacts

Kaiser Permanente Fontana Medical Center

Recruiting

Fontana, California, United States, 92335

Contacts

UCSD Health La Jolla

Recruiting

La Jolla, California, United States, 92037

Contacts

Kaiser Permanente Los Angeles Medical Center

Recruiting

Los Angeles, California, United States, 90027

Contacts

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Casa Colina Hospital

Recruiting

Pomona, California, United States, 91767

Contacts

Kaiser Permanente San Diego Medical Center

Recruiting

San Diego, California, United States, 92123

Contacts

Stanford University

Recruiting

Stanford, California, United States, 94305

Contacts

Intermountain Health - St. Mary's Medical Center

Recruiting

Grand Junction, Colorado, United States, 81501

Contacts

Yale New Haven Hospital

Recruiting

New Haven, Connecticut, United States, 06511

Contacts

UF Health Jacksonville

Recruiting

Jacksonville, Florida, United States, 32209

Contacts

Emory University Hospital

Recruiting

Atlanta, Georgia, United States, 30303

Contacts

Grady Memorial Hospital

Recruiting

Atlanta, Georgia, United States, 30303

Contacts

University of Iowa Medical Center

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

University of Kansas Hospital

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Boston Medical Center

Recruiting

Boston, Massachusetts, United States, 02118

Contacts

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

University of Michigan - University Hospital

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Mclaren Flint

Recruiting

Flint, Michigan, United States, 48532

Contacts

Abbott Northwestern Hospital

Recruiting

Minneapolis, Minnesota, United States, 55407

Contacts

M Health Fairview University of Minnesota Medical Center

Recruiting

Minneapolis, Minnesota, United States, 55414

Contacts

Regions Hospital

Recruiting

Saint Paul, Minnesota, United States, 55101

Contacts

Barnes-Jewish Hospital

Recruiting

St Louis, Missouri, United States, 63110

Contacts

SSM Health St. Louis University Hospital

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Kings County Hospital Center

Recruiting

Brooklyn, New York, United States, 11203

Contacts

NYU Langone Hospital - Brooklyn

Recruiting

Brooklyn, New York, United States, 11220

Contacts

New Hanover Regional Medical Center

Recruiting

Wilmington, North Carolina, United States, 28403

Contacts

Wake Forest Baptist Medical Center

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45267

Contacts

OSU Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Oklahoma University Medical Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Oregon Health & Science University Hospital

Recruiting

Portland, Oregon, United States, 97239

Contacts

Hospital of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Rhode Island Hospital

Recruiting

Providence, Rhode Island, United States, 02903

Contacts

Medical University of South Carolina University Hospital

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Methodist University Hospital

Recruiting

Memphis, Tennessee, United States, 38163

Contacts

University of Texas Health Science Center San Antonio

Recruiting

San Antonio, Texas, United States, 78229

Contacts

University of Utah Healthcare

Recruiting

Salt Lake City, Utah, United States, 84132

Contacts

UVA Medical Center

Recruiting

Charlottesville, Virginia, United States, 22908

Contacts

Bon Secours St. Mary's Hospital

Recruiting

Richmond, Virginia, United States, 23226

Contacts

Harborview Medical Center

Recruiting

Seattle, Washington, United States, 98104

Contacts

More Information

Sponsor

Stanford University

Last update posted

Nov 18, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.